Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 17,074 shares of the stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $1,076,003.48. Following the transaction, the chief executive officer owned 2,081,056 shares in the company, valued at $131,148,149.12. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Tempus AI Trading Down 6.3%
Shares of NASDAQ:TEM traded down $4.01 during mid-day trading on Thursday, hitting $59.61. The company had a trading volume of 5,290,938 shares, compared to its average volume of 6,229,094. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $89.09. The firm has a fifty day moving average price of $72.87 and a 200 day moving average price of $57.56. The company has a market capitalization of $10.87 billion, a PE ratio of -56.24 and a beta of 3.61.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.16. The firm had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The business's revenue was up 23.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. As a group, research analysts forecast that Tempus AI, Inc. will post -1.20 EPS for the current year.
Tempus AI News Summary
Here's some of the latest news about TEM:
- Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating substantial potential upside from the cited $59.61 reference price. This is analyst opinion, not a guarantee of performance. HC Wainwright rating information
- Neutral Sentiment: Comparisons with Natera and Grail emphasize Tempus’s AI-enabled data ecosystem, while noting Natera’s growth and positive free cash flow and Grail’s Galleri cancer test trials. These articles provide competitive context rather than a new company-specific catalyst. Natera vs. Tempus AI Grail vs. Tempus AI
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on TEM shares. Jefferies Financial Group upgraded shares of Tempus AI from an "underperform" rating to a "hold" rating and upped their price objective for the stock from $35.00 to $70.00 in a report on Tuesday, November 3rd. Roth Capital initiated coverage on shares of Tempus AI in a report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 price objective for the company. Robert W. Baird upped their target price on shares of Tempus AI from $85.00 to $92.00 and gave the stock an "outperform" rating in a report on Tuesday, November 3rd. Weiss Ratings upgraded Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, October 13th. Finally, The Goldman Sachs Group assumed coverage on Tempus AI in a research note on Monday, September 21st. They issued a "neutral" rating and a $75.00 price objective for the company. Eleven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tempus AI has a consensus rating of "Hold" and an average target price of $79.37.
Get Our Latest Research Report on Tempus AI
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. purchased a new position in shares of Tempus AI in the third quarter valued at $3,977,000. Integrated Wealth Concepts LLC lifted its holdings in Tempus AI by 44.3% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company's stock worth $296,000 after purchasing an additional 1,110 shares in the last quarter. Schwarz Investment Partners Inc. bought a new position in Tempus AI in the 3rd quarter worth about $109,000. New York State Common Retirement Fund boosted its stake in Tempus AI by 3.0% in the 3rd quarter. New York State Common Retirement Fund now owns 54,400 shares of the company's stock worth $4,455,000 after purchasing an additional 1,600 shares during the period. Finally, Allworth Financial LP boosted its stake in Tempus AI by 203.7% in the 3rd quarter. Allworth Financial LP now owns 2,542 shares of the company's stock worth $208,000 after purchasing an additional 1,705 shares during the period. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.